S aphenous vein graft failure from thrombosis occurs with remarkable frequency: approximately 3% to 12% within the first postoperative month 1 and 28% within the first postoperative year. 2 Vein graft thrombosis is generally attributed to alterations in the vessel wall and flow dynamics, vein graft endothelial damage associated with both vein harvest and vein graft distension by arterial pressure, and consequent compromise of anticoagulant vessel properties. 1 Among these factors, the most practical target for therapy appears to be maintenance or restoration of the vein graft endothelium.
Reendothelialization of vein grafts is a relatively slow process that involves proliferation and migration of both graft-intrinsic endothelial cells (ECs) and graft-extrinsic ECs, 3 which may derive from adjacent arterial endothelium or circulating endothelial progenitor cells (EPCs). 4, 5 Consequently, accelerating EC growth or increasing EC number with exogenous ECs may accelerate vein graft reendothelialization. Exogenous ECs derived from peripheral and umbilical cord blood EPCs are relatively easy to obtain and possess substantial replicative capacity. 6 Most studies that have examined adhesion of ECs to damaged vasculature have used ECs obtained from earlyoutgrowth cultures of EPCs, which are of a myeloid lineage and do not exhibit the antithrombotic properties of ECs. [7] [8] [9] Few vascular repair experiments have examined ECs derived from late-outgrowth cultures of EPCs isolated from adult or umbilical cord blood. These late-outgrowth EPCs, or endothelial colony-forming cells, exhibit characteristics only of ECs and not of monocytes. 10, 11 ECs obtained from lateoutgrowth cultures of peripheral blood EPCs (PB-ECs) from healthy donors and patients with coronary artery disease (CAD) are similar to aortic ECs with regard to proliferation, viability, adhesion, and antithrombotic function. 12 However, the clinical use of autologous PB-ECs is limited to elective procedures because of the time required to isolate and expand them in culture. The suitability of PB-ECs for vein graft repair may be further limited because PB-ECs cannot be isolated from a substantial minority of patients with CAD. 12 This limitation may be circumvented by using ECs derived from late-outgrowth cultures of human umbilical cord blood EPCs (hCB-ECs), which have demonstrated a variety of EC properties 13 and can be cultured in advance so that sufficient numbers are available for emergency procedures. To facilitate nonautologous transplantation, hCB-ECs can be matched to donors with compatible major histocompatibility class (MHC) I proteins. 14, 15 Compared with hCB lineage-negative mononuclear cells previously used to reduce vein graft neointimal hyperplasia, 16 hCB-ECs would be expected to exhibit more uniform EC function and to lack monocytic function.
To assess the suitability of hCB-ECs for therapeutic reendothelialization of vein grafts, we first compared the adhesion, integrin expression, and growth of hCB-ECs with ECs derived from late-outgrowth cultures of adult human PB-ECs and with human aortic ECs in vitro. Subsequently, we used hCB-ECs in immunocompromised mice subjected to vein grafting.
Methods
Expanded methods are provided in the supplemental material (available online at http://atvb.ahajournals.org).
Cell Culture and Adhesion Experiments
We isolated and cultured hCB-ECs, PB-ECs, and human aorta ECs (HAECs), as previously described, and characterized them regarding the expression of CD31, Krüppel-like factor (KLF)-2, endothelial NO synthase, and cyclooxygenase-2 and the lack of CD14 expression. 12, 13 Smooth muscle cells (SMCs) were prepared, as previously described, 17 and were plated at 80 000 cells per centimeter squared, with SMC growth media on fibronectin-coated polystyrene. After seeding, SMCs were maintained in serum-free medium for 7 days. One day before the experiment, the medium was replaced with serum-free medium containing extracellular matrix proteins (fibronectin, collagen I, and collagen III). To test adhesion, hCB-ECs, PB-ECs, or HAECs were superfused over SMCs in a parallel plate flow channel 18 at a shear stress of 0.5 dyne/cm 2 . After 10 minutes, the number of adherent cells per centimeter squared was determined. In integrin-blocking studies, ECs were incubated with anti-integrin IgGs for 30 minutes and then superfused over SMCs for 5 minutes. The net force imposed on the ECs during the dynamic adhesion experiments was determined by assuming that the ECs were spherical when initially adhered, as described in the supplemental methods.
Flow Cytometry and EC Proliferation
The expression of ␣ 5 ␤ 1 , ␣ V ␤ 3 , and ␣ 2 ␤ 1 integrins, present on the plasma membrane of hCB-ECs, PB-ECs, and HAECs, respectively, was determined by cell surface immunofluorescence and flow cytometry, as previously described. 13, 19 ECs were seeded at subconfluent density (25 000 cells/cm 2 ); after 15 minutes of static incubation, the ECs were placed inside a parallel plate flow chamber for 4 days. The number of cells present on days 0, 2, and 4 for static conditions and on days 0 and 4 for flow conditions was used to find the approximate doubling time of the cells.
Vein Graft Surgery and hCB-EC Injections
All animal experiments conformed to protocols approved by the Duke Institutional Animal Care and Use Committee. Interposition vein grafting of the common carotid artery was performed as previously described, 20 except that NOD.CB17-Prkdc scid /J ("SCID") mice were used, to avoid immune-mediated rejection of the hCB-EC xenotransplantation. Before infusion into mice, hCB-ECs were trypsinized and rinsed with trypsin-neutralizing solutions. The hCBECs were then resuspended in Iscove-modified Dulbecco medium (Invitrogen, Carlsbad, Calif) at 6.7ϫ10 6 cells per milliliter; 1ϫ10 6 hCB-ECs (or a corresponding volume of cell-free medium) were injected at surgery (33% directly into the vein graft lumen for 15 minutes before establishing vein graft blood flow and 67% intravenously). Four days postoperatively, 1ϫ10 6 hCB-ECs were again injected intravenously. Vein grafts were harvested 2 weeks postoperatively, placed in optimal cutting temperature medium, and frozen at Ϫ80°C before sectioning.
Histology
Serial vein graft sections were stained for CD31, which stains all ECs, and human MHC I, using hematoxylin-eosin and routine methods. 21, 22 To quantitate vein graft endothelialization and hCB-EC-derived endothelialization, we used computer software (ImageJ) from the National Institutes of Health to measure the vein graft luminal perimeter and the percentage of this perimeter that stained for CD31 alone or CD31 and (on serial sections) human MHC I, respectively (nϭ8 for both hCB-EC-and control-treated mice).
Data Analysis
Data are presented as meanϮSD in the text and meanϮSE in the figures. Proportions were analyzed by the Fisher exact test. Multiple group means were compared by 1-way ANOVA with the Tukey post hoc test for multiple comparisons.
Results

hCB-ECs Demonstrate Superior Dynamic Adhesion and Proliferation
Previously, we found that hCB-ECs express characteristic EC proteins (ie, von Willebrand factor, CD31, and VE-cadherin) but not the monocyte marker CD14. 13 Furthermore, we found that hCB-ECs responded to flow in a manner characteristic of vascular endothelium: by increasing NO release and upregulating mRNA for KLF-2, endothelial NO synthase, cyclooxygenase-2, and thrombomodulin. 13 For the current study, we first compared hCB-ECs, PB-ECs, and HAECs with regard to CD31 and VE-cadherin expression and found all EC types to be homogenously equivalent ( Figure 1A and data not shown).
Because the goal of this study was to mitigate vein graft disease with exogenous ECs, we sought to test EC adhesion by using a model of the vein graft's subendothelial surface exposed after the vein is overdistended by arterial pressure, when ECs and their basement membrane no longer cover the entire luminal surface of the vein graft. 23 This subendothelial surface of the vein comprises interstitial collagens I and III and fibronectin, 24, 25 in addition to basement membrane constituents, such as laminin and collagen IV. 24 We used cultured quiescent SMCs to model this subendothelial surface and found, by immunofluorescence, that the endogenous SMC matrix includes fibronectin, laminin, and collagens I, III, and IV (supplemental Figure I and data not shown). To augment EC adhesion to SMC monolayers, we adsorbed exogenous fibronectin, collagen I, and collagen III to the SMCs (supplemental Figure II) . Next, we compared dynamic adhesion among hCB-ECs, PB-ECs from healthy subjects, PB-ECs from subjects with CAD, and HAECs, at a shear stress of 0.5 dyne/cm 2 . After dynamic adhesion for 10 minutes, hCB-ECs adhered approximately 3 times greater than HAECs or PB-ECs from healthy adults (PB-ECs[healthy]) ( Figure 1B) .
One possible explanation for the superior adhesion of hCB-ECs derives from their size: the cross-sectional area of hCB-ECs was significantly smaller than that of other ECs: 239Ϯ10 m 2 for hCB-ECs and 464Ϯ46, 692Ϯ40, and 428Ϯ22 m 2 for PB-ECs(CAD), PB-ECs(healthy), and HAECs, respectively (PϽ0.05). Consequently, the force exerted by flowing medium on hCB-ECs was only half that exerted on other ECs (Equations 2a-2c in the supplemental materials). Indeed, an inverse relationship between adhesion and net force per cell was observed ( Figure 1C) .
Another potentially important factor in determining EC adhesion under shear stress is EC integrin activity. By using IgG to block integrins ␣ 5 ␤ 1 , ␣ V ␤ 3 , or ␣ 2 ␤ 1 , we found that dynamic adhesion of hCB-ECs to an SMC/matrix substrate was strongly dependent on the ␣ 5 ␤ 1 and ␣ V ␤ 3 integrins (Figure 2A) . By using SMC monolayers in the absence of exogenous matrix proteins, concordant findings were previously obtained: ␣ 5 ␤ 1 and ␣ V ␤ 3 integrins mediated static adhesion of hCB-ECs. 13 To determine whether EC typespecific expression levels of ␣ 5 ␤ 1 or/and ␣ V ␤ 3 integrins could explain why hCB-ECs adhere to the SMC/matrix substrate more avidly than other ECs ( Figure 1B ), we quantitated cell surface integrin expression on all of our EC types by flow cytometry. The cell surface expression of the ␣ 5 ␤ 1 integrin was approximately 45% higher on hCB-ECs than on PB-ECs or HAECs ( Figure 2B ), and the cell surface expression of ␣ V ␤ 3 was similar on all EC types ( Figure 2B) . Thus, because all EC types expressed similar ␣ V ␤ 3 integrin levels, the superior adhesion of hCB-ECs seems unlikely to derive from their ␣ V ␤ 3 integrin expression. Rather, the superior adhesion of hCB-ECs may derive in part from higher expression levels of cell surface ␣ 5 ␤ 1 integrins. These experiments do not exclude the possibility that superior hCB-EC dynamic adhesion also derives from additional integrins or hCB-EC-specific differences in integrin-promoted signaling.
The adhesion of ECs to deendothelialized vascular surfaces would optimally be followed by EC proliferation to facilitate reendothelialization. Accordingly, we tested the ability of hCB-ECs, PB-ECs, and HAECs to proliferate under static and flow conditions on fibronectin-coated plastic. Although EC proliferation declined with shear stress, hCB-ECs demonstrated doubling times that were 4 to 13.7 times shorter than those of PB-ECs and HAECs under flow conditions (Table) .
hCB-ECs Reendothelialize Vein Grafts and Eliminate Thrombosis
Because hCB-ECs demonstrated adhesion and proliferation that was superior to PB-ECs and HAECs, we tested the ability The bar indicates 50 m. B, The indicated type of EC was suspended at 500 000 cells per milliliter and superfused for 10 minutes over quiescent SMCs, to which exogenous fibronectin, collagen I, and collagen III were absorbed to augment adhesion (supplemental Figure I) . The flow velocity used created a shear stress of 0.5 dyne/cm 2 . The number of adherent ECs is plotted as the meanϮSE from 4 independent experiments. Compared with PB-EC(healthy) and HAECs: *PϽ0.05. C, The number of adherent ECs is plotted against the net fluid force acting on ECs exposed to 0.5 dyne/cm 2 . The net fluid force was calculated as described in the supplemental methods. (Figure 3) .
To test the hypothesis that hCB-ECs prevented vein graft thrombosis by accelerating vein graft reendothelialization, we immunostained vein grafts for the EC marker CD31, using an IgG that recognizes both human and mouse proteins. Judging by the percentage of vein graft luminal surface that stained with CD31, we found endothelialization of vein grafts from hCB-EC-injected mice to be approximately 4-fold greater than that in control-injected mice with patent vein grafts ( Figure 4 ): 54Ϯ6% versus 14Ϯ1% of the luminal surface was covered with CD31-staining cells in vein grafts from hCB-EC-and sham-treated mice, respectively.
To determine the contribution of injected hCB-ECs to vein graft reendothelialization, we calculated the percentage of CD31-positive cells that stained for human MHC I antigen on serial sections of the vein grafts. Vein grafts from mice that were not injected with hCB-ECs demonstrated no staining for human MHC I (data not shown). In contrast, the endothelium in vein grafts from mice that were injected with hCB-ECs did stain for human MHC I (ie, 33Ϯ6% of the endothelium present in the 2-week-old vein grafts) (Figure 4) . Thus, injected hCB-ECs engrafted on the vein graft subendothelial surface and contributed approximately 33% of the ECs during their reendothelialization.
Discussion
To our knowledge, these studies demonstrate for the first time that hCB-ECs adhere to extracellular matrix or SMCs and proliferate under flow conditions not only in vitro but also in vein grafts in vivo. The adhesive properties of the EPCderived hCB-ECs in vitro proved superior to those of several lines of adult EPC-derived ECs and aortic ECs. Furthermore, the adhesion of hCB-ECs to vein grafts in vivo prevented vein graft thrombosis.
The greater adhesion of hCB-ECs compared with adult primary ECs is likely influenced by the higher expression of ␣ 5 ␤ 1 integrins and the smaller relative size of hCB-ECs. The inverse relation between the force and number of adherent ECs per centimeter squared ( Figure 1C) suggests that the force acting on the cell strongly influences adhesion. EC size affects adhesion in 2 potentially competing ways. First, larger cells experience a greater fluid force and the net fluid force on the cell increases with the square of the cell radius (Equations 2a-2c in the supplemental methods). Second, the contact area between the EC and surface increases with EC radius and equals 2hR, where h is the distance over which adhesion bonds can form and R is the cell radius. The contact area and receptor number are related to the force exerted by the bonds (f b ), which is approximately N R A C f b ϭN R 2hRf b , where N R represents the number of receptors per unit cell surface area and f b is the force per bond. 26 The bond force increases linearly with cell radius, whereas the fluid force increases with R 2 . After accounting for the effect of force and contact area on adhesion, increasing cell size should lead to reduced adhesion, as long as receptor expression levels are similar. The relative change in force per cell for 2 cell types of different sizes is N R 2 R 2 /N R 1 R 1 . By using Figure 2B to obtain the ␣ 5 ␤ 1 integrin levels and measurements of the cell radius, this ratio between hCB-ECs and the other EC types is close to 1 for all cell types, except for PB-ECs from healthy individuals (0.6Ϯ0.2). Thus, the increased contact area for larger cells is offset by the higher receptor expression on hCB-ECs, and the net fluid force acting on the cells is the dominant factor influencing adhesion of the different cell types.
Cell size also affects the likely retention of ECs in the microcirculation. The larger PB-ECs and HAECs are more likely to be limited in their ability to pass through capillaries than the smaller hCB-ECs. However, the hCB-ECs (radius, 8.4 m) are larger than monocytes (radius, 6.1 m) 27 and neutrophils (radius, 4.1 m). 28 Thus, ECs injected into the circulation may be trapped predominantly in the microcirculation. Indeed, autologous EPC-derived ECs infused intravenously have been sequestered in the spleen. 29 Therefore, the most critical steps in promoting EC attachment to the vein graft may occur during static incubation with the vein graft and initial adhesion after injection.
By demonstrating the antithrombotic therapeutic efficacy of hCB-EC infusion, our vein graft studies exploited an unusual tendency to thrombosis in NOD.CB17-Prkdc scid /J mice. Although thrombosis occurred in approximately 75% of our IVC carotid interposition isografts in NOD.CB17-Prkdc scid /J mice, thrombosis occurs in only approximately 2% of our IVC carotid interposition isografts in C57BL/6 mice, with or without the SCID mutation. 16,20 -22 The mechanisms by which hCB-EC infusion achieves antithrombotic efficacy in NOD.CB17-Prkdc scid /J mice remain to be determined. However, based on our current data, it seems likely that these mechanisms include a reduction in the area of the subendothelial surface exposed to blood and the host of antithrombotic properties inherent in hCB-ECs. 13 Previous studies 30, 31 have shown that thrombosis is inhibited in vitro by EPC-derived ECs. Furthermore, thrombosis of decellularized iliac arteries is inhibited in vivo when these arteries are preseeded in vitro with autologous EPC-derived ECs in a manner that achieves full reendothelialization. 32 Our results are consistent with these studies and demonstrate that infused hCB-ECs adhere to the vein graft luminal surface and inhibit thrombosis, even without complete coverage of the luminal surface. The inhibition of thrombosis in the context of incomplete reendothelialization may rely in part on prostacyclin secreted by the hCB-ECs. 30 Of course, the optimal hCB-EC dose and route of administration for preventing vein graft thrombosis remain to be established.
The adhesion of hCB-ECs to the vein grafts is likely facilitated by the reduction in shear stress attendant to the relatively large diameter of the vein grafts used. Assuming unilateral common carotid blood flow of 0.28 mL/min 33 and a common carotid artery radius of 0.15 mm, 34 Equation 3 in the supplemental material can be used to infer that normal carotid shear stress would be approximately 52 dyne/cm 2 , which is slightly higher than another report of 35 dyne/cm 2 . 35 However, if we assume that overall carotid flow and pressure are not altered by the vein graft, we can infer that shear stress in the vein graft is only approximately 1.7 dyne/cm 2 because the radius of the IVC carotid interposition graft is approximately 0.47 mm postoperatively. 20 Because it was performed in a highly thrombogenic mouse model, our study may overestimate the true benefit of hCB-EC therapy for vein graft thrombosis in humans. Moreover, from a therapeutic perspective, using hCB-ECs to prevent human vein graft thrombosis would require matching donor hCB-ECs and the recipient for MHC antigens. 15 When stimulated with interferon ␥ or tumor necrosis factor, even late-outgrowth hCB-ECs have expressed significant levels of MHC I, MHC II, and adhesion molecules; and have stimulated proliferation of allogeneic CD4 ϩ T lymphocytes. 15 Moreover, EC tubes formed in SCID mice by hCB-ECs are destroyed when these mice are injected with PB mononuclear cells that are allogeneic to the hCB-ECs. 15 The high proliferative capacity of hCB-ECs 14 may facilitate matching these ECs for MHC antigens to subjects undergoing vein grafting.
In a physiological model of vein grafting, 20 our hBC-EC reendothelialization and antithrombotic data accord well with studies [7] [8] [9] that demonstrate enhanced reendothelialization of injured arteries with administration of PB-ECs. However, it seems likely that there would be a therapeutic advantage associated with the superior adhesive and proliferative properties of hCB-ECs. It remains to be determined whether in vivo comparisons of hCB-ECs with other EPC-derived ECs will support this hypothesis.
